Germline variants associated with immunotherapy-related adverse events
Stefan Groha, Sarah Abou Alaiwi, Wenxin Xu, View ORCID ProfileVivek Naranbhai, Amin H. Nassar, View ORCID ProfileZiad Bakouny, Elio Adib, Pier V. Nuzzo, Andrew L. Schmidt, Chris Labaki, Talal El Zarif, Biagio Ricciuti, Joao Victor Alessi, David A. Braun, Sachet A. Shukla, Tanya E. Keenan, View ORCID ProfileEliezer Van Allen, Mark M. Awad, Michael Manos, Osama Rahma, Leyre Zubiri, Alexandra-Chloe Villani, Christian Hammer, View ORCID ProfileZia Khan, Kerry Reynolds, Yevgeniy Semenov, Deborah Schrag, Kenneth L. Kehl, Matthew L. Freedman, Toni K. Choueiri, Alexander Gusev
doi: https://doi.org/10.1101/2022.04.10.22273627
Stefan Groha
1Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2Broad Institute of Harvard & MIT, Cambridge, MA, USA
13Harvard Medical School, Boston, MA, USA
Sarah Abou Alaiwi
3Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Wenxin Xu
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Vivek Naranbhai
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Amin H. Nassar
3Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
4Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
Ziad Bakouny
4Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Elio Adib
3Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
4Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
Pier V. Nuzzo
3Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
6Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy
Andrew L. Schmidt
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Chris Labaki
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Talal El Zarif
3Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Biagio Ricciuti
8Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Joao Victor Alessi
8Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
David A. Braun
3Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Sachet A. Shukla
2Broad Institute of Harvard & MIT, Cambridge, MA, USA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
7Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA
Tanya E. Keenan
2Broad Institute of Harvard & MIT, Cambridge, MA, USA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
9Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA
Eliezer Van Allen
2Broad Institute of Harvard & MIT, Cambridge, MA, USA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
10Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA
Mark M. Awad
8Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Michael Manos
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Osama Rahma
4Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Leyre Zubiri
11Massachusetts General Hospital, Boston, MA, USA
Alexandra-Chloe Villani
2Broad Institute of Harvard & MIT, Cambridge, MA, USA
12Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
13Harvard Medical School, Boston, MA, USA
Christian Hammer
17Genentech, South San Francisco, CA, USA
Zia Khan
17Genentech, South San Francisco, CA, USA
Kerry Reynolds
13Harvard Medical School, Boston, MA, USA
14Division of Medical Oncology, Bartlett, Massachusetts General Hospital, Boston, MA, USA
Yevgeniy Semenov
15Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA
Deborah Schrag
1Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Kenneth L. Kehl
1Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Matthew L. Freedman
2Broad Institute of Harvard & MIT, Cambridge, MA, USA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Toni K. Choueiri
3Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
4Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
13Harvard Medical School, Boston, MA, USA
Alexander Gusev
1Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2Broad Institute of Harvard & MIT, Cambridge, MA, USA
13Harvard Medical School, Boston, MA, USA
16Division of Genetics, Brigham and Women’s Hospital, Boston, MA, USA
- Supplemental Materials[supplements/273627_file02.pdf]
Posted April 15, 2022.
Germline variants associated with immunotherapy-related adverse events
Stefan Groha, Sarah Abou Alaiwi, Wenxin Xu, Vivek Naranbhai, Amin H. Nassar, Ziad Bakouny, Elio Adib, Pier V. Nuzzo, Andrew L. Schmidt, Chris Labaki, Talal El Zarif, Biagio Ricciuti, Joao Victor Alessi, David A. Braun, Sachet A. Shukla, Tanya E. Keenan, Eliezer Van Allen, Mark M. Awad, Michael Manos, Osama Rahma, Leyre Zubiri, Alexandra-Chloe Villani, Christian Hammer, Zia Khan, Kerry Reynolds, Yevgeniy Semenov, Deborah Schrag, Kenneth L. Kehl, Matthew L. Freedman, Toni K. Choueiri, Alexander Gusev
medRxiv 2022.04.10.22273627; doi: https://doi.org/10.1101/2022.04.10.22273627
Germline variants associated with immunotherapy-related adverse events
Stefan Groha, Sarah Abou Alaiwi, Wenxin Xu, Vivek Naranbhai, Amin H. Nassar, Ziad Bakouny, Elio Adib, Pier V. Nuzzo, Andrew L. Schmidt, Chris Labaki, Talal El Zarif, Biagio Ricciuti, Joao Victor Alessi, David A. Braun, Sachet A. Shukla, Tanya E. Keenan, Eliezer Van Allen, Mark M. Awad, Michael Manos, Osama Rahma, Leyre Zubiri, Alexandra-Chloe Villani, Christian Hammer, Zia Khan, Kerry Reynolds, Yevgeniy Semenov, Deborah Schrag, Kenneth L. Kehl, Matthew L. Freedman, Toni K. Choueiri, Alexander Gusev
medRxiv 2022.04.10.22273627; doi: https://doi.org/10.1101/2022.04.10.22273627
Subject Area
Subject Areas
- Addiction Medicine (394)
- Allergy and Immunology (706)
- Anesthesia (197)
- Cardiovascular Medicine (2887)
- Dermatology (247)
- Emergency Medicine (433)
- Epidemiology (12629)
- Forensic Medicine (10)
- Gastroenterology (814)
- Genetic and Genomic Medicine (4490)
- Geriatric Medicine (410)
- Health Economics (717)
- Health Informatics (2873)
- Health Policy (1059)
- Hematology (380)
- HIV/AIDS (912)
- Medical Education (418)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4258)
- Nursing (228)
- Nutrition (625)
- Oncology (2229)
- Ophthalmology (636)
- Orthopedics (255)
- Otolaryngology (323)
- Pain Medicine (272)
- Palliative Medicine (83)
- Pathology (491)
- Pediatrics (1183)
- Primary Care Research (489)
- Public and Global Health (6842)
- Radiology and Imaging (1504)
- Respiratory Medicine (910)
- Rheumatology (431)
- Sports Medicine (377)
- Surgery (476)
- Toxicology (60)
- Transplantation (206)
- Urology (176)